Preparation method of eye drops for treating glaucoma, cataract and vitreous opacification

Abstract

The invention discloses a preparation method of eye drops for treating glaucoma, cataract and vitreous opacification. The eye drops comprise the following components: berberine, N-acetyl carnosine and lycium barbarum polysaccharide. The specific formula comprises the following components: 0.1%-0.5% of berberine, 1%-3% of N-acetyl carnosine and 0.5%-2% of lycium barbarum polysaccharide. The invention belongs to the technical field of ophthalmic pharmaceutical preparations, and solves the problems that in the prior art, glaucoma, cataract and vitreous opacity generally need to be separately taken, the research on compound preparations is less, and the components possibly interact with one another.

Description

Technical Field

[0001] The present invention belongs to the technical field of ophthalmic pharmaceutical preparations, and specifically refers to a preparation method of eye drops for treating glaucoma, cataract, and vitreous opacity. Background Art

[0002] Vitreous opacity, glaucoma, and cataract have certain commonalities in some aspects, including etiological factors, physiological mechanisms, clinical manifestations, and treatment methods. The following is an analysis of their main commonalities: Common etiological factors: 1. Age factor. For vitreous opacity, with the increase of age, vitreous liquefaction and aggregation of collagen fibers form turbidity. For cataract, lens protein denaturation leads to turbidity. For glaucoma, the aqueous humor drainage system degenerates. 2. Metabolic diseases, such as diabetes. Diabetes can cause: vitreous opacity, diabetic retinopathy leading to vitreous hemorrhage. Cataract, high blood sugar causes changes in the osmotic pressure of the lens, accelerating turbidity. Glaucoma, neovascular glaucoma, caused by retinal ischemia. 3. Oxidative stress and free radical damage. All three are related to the damage of ocular tissues caused by the accumulation of free radicals, and antioxidant therapy has a certain effect on delaying the progression. 4. Ultraviolet or radiation exposure. Long-term ultraviolet irradiation may increase the risk of cataract, that is, lens protein denaturation and glaucoma, but has little effect on vitreous opacity.

[0003] In summary, although the etiologies and lesion sites of vitreous opacity, glaucoma, and cataract are different, they have commonalities in aspects such as aging, metabolic disorders, and oxidative damage. For high-risk populations, comprehensive prevention and control are required.

[0004] In the prior art, glaucoma, cataract, and vitreous opacity usually require separate medications, such as prostaglandin-like intraocular pressure-lowering drugs and antioxidants to delay cataract, and the patient compliance is poor. Summary of the Invention

[0005] The technical problem to be solved by the present invention is that in the prior art, glaucoma, cataract, and vitreous opacity usually require separate medications, there is less research on compound preparations, and there may be interactions between components.

[0006] The technical solution adopted by the present invention is as follows: The present invention provides a preparation method of eye drops for treating glaucoma, cataract, and vitreous opacity, which comprises the following components: berberine, N-acetylcarnosine, and wolfberry polysaccharide.

[0007] Its specific formula includes the following components: berberine 0.1% - 0.5%, N-acetylcarnosine 1% - 3%, and wolfberry polysaccharide 0.5% - 2%.

[0008] Furthermore, it also comprises excipients: osmotic pressure regulator 0.5% - 1%, pH buffer 0.01% - 0.1%, and preservative 0.005% - 0.02%.

[0009] Further, the pH buffer is a borate buffer solution with a pH value of 6.5 to 7.5.

[0010] Further, it includes the following steps:

[0011] Step 1: Dissolve berberine in an acid solution and filter to sterilize.

[0012] Step 2: Dissolve N-acetylcarnosine and wolfberry polysaccharide in water and mix with the aforementioned solution.

[0013] Step 3: Add excipients and adjust the pH, then filter and dispense.

[0014] Further, the filtration uses a 0.22 μm microporous membrane.

[0015] The beneficial effects achieved by the present invention with the above structure are as follows: reducing intraocular pressure, inhibiting the denaturation of lens proteins and promoting vitreous metabolism through synergistic effects; the preparation process of the liquid of the present invention is simple and has high stability, and can provide non-invasive treatment for three kinds of eye diseases simultaneously. Specific embodiments

[0016] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments; based on the embodiments in the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts shall fall within the protection scope of the present invention.

[0017] Example 1:

[0018] A preparation method of eye drops for treating glaucoma, cataract and vitreous opacity, comprising the following components: berberine, N-acetylcarnosine, wolfberry polysaccharide; its specific formula includes the following components: berberine 0.1% - 0.5%, N-acetylcarnosine 1% - 3%, wolfberry polysaccharide 0.5% - 2%.

[0019] It also includes excipients: osmotic pressure regulator 0.5% - 1%, pH buffer 0.01% - 0.1%, preservative 0.005% - 0.02%.

[0020] The pH buffer is a borate buffer solution with a pH value of 6.5.

[0021] It includes the following steps:

[0022] Step 1: Dissolve berberine in an acid solution and filter to sterilize.

[0023] Step 2: Dissolve N-acetylcarnosine and wolfberry polysaccharide in water and mix with the aforementioned solution.

[0024] Step 3: Add excipients and adjust the pH, then filter and dispense.

[0025] The filtration uses a 0.22 μm microporous filter membrane.

[0026] Example 2:

[0027] A preparation method of eye drops for treating glaucoma, cataract and vitreous opacity, comprising the following components: berberine, N-acetylcarnosine, and wolfberry polysaccharide; its specific formula includes the following components: berberine 0.1% - 0.5%, N-acetylcarnosine 1% - 3%, and wolfberry polysaccharide 0.5% - 2%.

[0028] It also contains excipients: osmotic pressure regulator 0.5% - 1%, pH buffer 0.01% - 0.1%, and preservative 0.005% - 0.02%.

[0029] The pH buffer is borate buffer solution with a pH value of 7.5.

[0030] It includes the following steps:

[0031] Step 1: Dissolve berberine in an acid solution and filter to sterilize.

[0032] Step 2: Dissolve N-acetylcarnosine and wolfberry polysaccharide in water and mix with the aforementioned solution.

[0033] Step 3: Add excipients and adjust the pH, then filter and package.

[0034] The filtration uses a 0.22 μm microporous filter membrane.

[0035] It should be noted that in this article, relational terms such as first and second are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual relationship or order between these entities or operations. Moreover, the term "comprises", "comprising" or any other variation thereof is intended to cover a non-exclusive inclusion, such that a process, method, article or device comprising a series of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, method, article or device.

[0036] Although the embodiments of the present invention have been shown and described, it will be understood by those of ordinary skill in the art that various changes, modifications, substitutions and variations can be made to these embodiments without departing from the principles and spirit of the present invention, and the scope of the present invention is defined by the appended claims and their equivalents.

[0037] The above description of the present invention and its implementation manners is not restrictive. Generally speaking, if those of ordinary skill in the art are inspired by it and, without departing from the gist of the present invention, creatively design structural manners and embodiments similar to the technical solution, they shall fall within the protection scope of the present invention.

Claims

1. A kind of eye drops for treating glaucoma, cataract and vitreous opacity, characterized in that: It contains the following components: berberine, N-acetyl carnosine, and wolfberry polysaccharide; Its specific formula includes the following components: berberine 0.1% - 0.5%, N-acetyl carnosine 1% - 3%, and wolfberry polysaccharide 0.5% - 2%.

2. The eye drops for treating glaucoma, cataract and vitreous opacity according to claim 1, wherein: It also contains excipients: osmotic pressure regulator 0.5% - 1%, pH buffer 0.01% - 0.1%, and preservative 0.005% - 0.02%.

3. The eye drops for treating glaucoma, cataract and vitreous opacity according to claim 2, characterized in that: The pH buffer is borate buffer solution with a pH value of 6.5 - 7.

5.

4. The preparation method of the eye drops for treating glaucoma, cataract and vitreous opacity according to any one of claims 1-3, characterized in that: It includes the following steps: Step 1: Dissolve berberine in an acid solution and filter to sterilize; Step 2: Dissolve N-acetyl carnosine and wolfberry polysaccharide in water and mix with the aforementioned solution; Step 3: Add excipients and adjust the pH, then filter and dispense.

5. The preparation method of the eye drops for treating glaucoma, cataract and vitreous opacity according to claim 4, characterized in that: The filtration uses a 0.22μm microporous membrane.